Patents by Inventor Wayne Front March

Wayne Front March has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100185066
    Abstract: An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence traveling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio of the first fluorescence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.
    Type: Application
    Filed: January 24, 2010
    Publication date: July 22, 2010
    Inventor: Wayne Front MARCH
  • Patent number: 7653424
    Abstract: An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence traveling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio of the first fluorescence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: January 26, 2010
    Assignee: Eyesense AG
    Inventor: Wayne Front March
  • Patent number: 6980842
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: December 27, 2005
    Assignee: Novartis
    Inventors: Wayne Front March, Mary Flowers Mowery-McKee
  • Patent number: 6850786
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, inidicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: February 1, 2005
    Assignee: Novartis AG
    Inventor: Wayne Front March
  • Publication number: 20040152963
    Abstract: An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence travelling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio or the first fluorecence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.
    Type: Application
    Filed: March 26, 2004
    Publication date: August 5, 2004
    Inventor: Wayne Front March
  • Publication number: 20040059207
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, inidicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Application
    Filed: September 3, 2003
    Publication date: March 25, 2004
    Inventor: Wayne Front March
  • Patent number: 6681127
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: January 20, 2004
    Assignee: Novartis AG
    Inventor: Wayne Front March
  • Publication number: 20030045783
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Application
    Filed: October 11, 2002
    Publication date: March 6, 2003
    Inventors: Wayne Front March, Mary Flowers Mowery-McKee
  • Publication number: 20020007113
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Application
    Filed: July 6, 2001
    Publication date: January 17, 2002
    Inventors: Wayne Front March, Mary Flowers Mowery-McKee
  • Publication number: 20010034500
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Application
    Filed: February 15, 2001
    Publication date: October 25, 2001
    Inventor: Wayne Front March
  • Patent number: 3958560
    Abstract: A unique glucose sensor to determine the glucose level in patients, for example, for use in treating or diagnosing diabetes. The patient's eye is automatically scanned using a source of radiation at one side of the patient's cornea. A sensor located at the other side of the cornea detects the radiation that passed through the cornea. The level of glucose in the bloodstream of the patient is a function of the amount of radiation detected at the other side of the cornea of the patient. The result is transmitted to a remote receiver that is coupled to a readout device to thereby provide non-invasive glucose determinations.
    Type: Grant
    Filed: November 25, 1974
    Date of Patent: May 25, 1976
    Inventor: Wayne Front March